Postmortem validation of imaging biomarkers for Lewy body disease


  • For those with Lewy body diseases, [11C]Altropane dopamine transporter (DAT) imaging detects substantia nigra degeneration and [11C]Pittsburgh compound B (PiB) PET imaging accurately captures cortical amyloid deposits.

Why this matters

  • The post-mortem validation of these molecular imaging techniques supports the use of these imaging modalities as biomarkers for the diagnosis and monitoring of Lewy body diseases.